Sodium Nitrate vs Recombinant Bovine Growth Hormone: which is worse?

What is Sodium Nitrate?

Sodium nitrate (NaNO3) is a naturally occurring salt found in soil and some plants, and also synthetically produced for use as a food preservative and curing agent. It is converted to sodium nitrite by bacterial action in foods or in the body, where it exerts its preservative and curing effects. Sometimes called 'Chile saltpeter' after its natural South American ore source.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Sodium Nitrate: Sodium nitrate shares the same health concerns as sodium nitrite: conversion to nitrosamines is the primary mechanism of concern. Sodium nitrate is converted to nitrite by bacterial reduction in foods and by nitrate-reducing bacteria in saliva before reaching the stomach. The subsequent conversion of nitrite to nitrosamines carries the same carcinogenicity concerns described for sodium nitrite. IARC's 2015 classification of processed meat as Group 1 human carcinogen applies to all nitrite/nitrate-cured processed meats. EFSA's 2017 re-evaluation established acceptable daily intakes (ADIs) for nitrate (3.7 mg/kg body weight/day) and nitrite (0.07 mg/kg body weight/day) based on risk assessment. A notable paradox in nitrate nutrition: dietary nitrate from vegetables (particularly leafy greens like spinach, arugula, and lettuce, and root vegetables like beets) is associated with cardioprotective effects through the nitrate-nitrite-NO pathway, where nitric oxide from dietary nitrate improves vascular function and reduces blood pressure. This beneficial effect of vegetable nitrate contrasts with the potential harm from processed meat nitrate/nitrite, suggesting that the food matrix and associated compounds (antioxidants in vegetables vs. amines in meat protein) significantly influence whether nitrite produces beneficial or harmful effects. Infant exposure to high nitrate levels — particularly from well water — can cause methemoglobinemia ('blue baby syndrome'). The EU and WHO set strict nitrate limits for infant water and food for this reason.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.